,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2012-01-24 05:30:00,"Chicago, IL - January 24, 2012 - Zacks Equity Research highlights Caterpillar, Inc. ( CAT ) as the Bull of the Day and NII Holdings, Inc. ( NIHD ) as the Bear of the Day.",0.6977609992027283,0.01825244352221489,0.2839866280555725,positive,0.6795085668563843
1,2012-01-24 05:30:00,"In addition, Zacks Equity Research provides analysis on Lowe's Companies Inc. ( LOW ), Home Depot Inc. ( HD ) and St.Jude Medical ( STJ ).",0.023563772439956665,0.00750085199251771,0.9689353108406067,neutral,0.016062920913100243
2,2012-01-24 05:30:00,Full analysis of all these stocks is available at http://at.zacks.com/?id=2678 .,0.014196079224348068,0.008602765388786793,0.9772011041641235,neutral,0.0055933138355612755
3,2012-01-24 05:30:00,"Here is a synopsis of all five stocks:

Caterpillar, Inc. ( CAT ) posted an impressive third quarter with record EPS of $1.93 and sales of $14.6 billion driven by increased machine demand and continued economic growth.",0.9452483057975769,0.01527926605194807,0.03947242349386215,positive,0.9299690127372742
4,2012-01-24 05:30:00,Results were ahead of Zacks Consensus Estimates.,0.5820797681808472,0.06274291127920151,0.35517728328704834,positive,0.5193368792533875
5,2012-01-24 05:30:00,"With the Bucyrus acquisition, the company is positioned to be the #1 mining equipment manufacturer in the U.S. with a strong footing in China and India, the major mining markets.",0.9241149425506592,0.013953158631920815,0.06193193048238754,positive,0.9101617932319641
6,2012-01-24 05:30:00,Caterpillar's financial position continues to strengthen through the first nine months of the year.,0.9401602745056152,0.014283014461398125,0.0455566868185997,positive,0.9258772730827332
7,2012-01-24 05:30:00,Caterpillar's cash flow for the period is an all-time high and better than the company's full-year results so far.,0.949415385723114,0.026137858629226685,0.024446813389658928,positive,0.9232774972915649
8,2012-01-24 05:30:00,"Furthermore, the company's order backlog has steadily increased throughout the year and is at a record level, which holds promise for the year ahead.",0.9487003684043884,0.015947049483656883,0.03535263612866402,positive,0.932753324508667
9,2012-01-24 05:30:00,We upgrade our recommendation from Neutral to Outperform and set a target price of $127.,0.6720728874206543,0.017816562205553055,0.31011056900024414,positive,0.6542563438415527
10,2012-01-24 05:30:00,"We downgrade our recommendation on NII Holdings, Inc. ( NIHD ) to Underperform backed by our assessment that the company s nightmare will continue in the near future.",0.04330980032682419,0.9321712255477905,0.024518977850675583,negative,-0.8888614177703857
11,2012-01-24 05:30:00,NII Holdings reported dismal financial results for the third quarter of 2011.,0.020382171496748924,0.9651632308959961,0.01445469819009304,negative,-0.9447810649871826
12,2012-01-24 05:30:00,Both the top line and bottom line were well below the Zacks Consensus Estimates.,0.020542103797197342,0.9406524896621704,0.03880535811185837,negative,-0.9201104044914246
13,2012-01-24 05:30:00,"Management has slashed its fiscal 2011 financial outlook, mainly driven by the volatile macro-economic condition coupled with significant depreciation of several Latin American currencies in comparison with U.S. dollars.",0.018476316705346107,0.967187762260437,0.014335840940475464,negative,-0.9487114548683167
14,2012-01-24 05:30:00,"Moreover, stiff competitive scenarios in Latin American markets are other impediments for such a reduced outlook.",0.06198988854885101,0.773816704750061,0.16419345140457153,negative,-0.7118268013000488
15,2012-01-24 05:30:00,We believe intensifying competition and increased promotional expenses may reduce the company's near-term growth opportunities.,0.036748006939888,0.9324093461036682,0.030842645093798637,negative,-0.8956613540649414
16,2012-01-24 05:30:00,We do not find any immediate catalysts and expect NII Holdings to report weak financial results for the company's 4th quarter.,0.018390564247965813,0.9639930725097656,0.017616312950849533,negative,-0.945602536201477
17,2012-01-24 05:30:00,"The growth of home improvement companies is directly proportional to the housing market cycles, which in turn is closely related with the prevailing economic conditions.",0.04045809805393219,0.0049447230994701385,0.9545972347259521,neutral,0.03551337495446205
18,2012-01-24 05:30:00,A tremor at one end obviously makes its rippling effects evident on the other end too.,0.04994658753275871,0.05833487585186958,0.8917185664176941,neutral,-0.00838828831911087
19,2012-01-24 05:30:00,"Remember the subprime crisis, which destabilized the U.S. housing market?",0.06205790117383003,0.1444162279367447,0.7935258746147156,neutral,-0.08235833048820496
20,2012-01-24 05:30:00,"Thus Lowe's Companies Inc. ( LOW ), being the world's second largest home improvement retailer, will have to walk the tight rope.",0.22368010878562927,0.08052609860897064,0.6957937479019165,neutral,0.14315401017665863
21,2012-01-24 05:30:00,Lowe's expects fourth-quarter 2011 earnings in the range of 20 cents to 23 cents a share.,0.1386422961950302,0.009435521438717842,0.8519221544265747,neutral,0.12920677661895752
22,2012-01-24 05:30:00,"For fiscal 2011, management expects earnings between $1.57 and $1.60 per share, excluding charges of 20 cents related to store closings and discontinued operations.",0.03648554906249046,0.055972468107938766,0.9075419306755066,neutral,-0.019486919045448303
23,2012-01-24 05:30:00,The current Zacks Consensus Estimate for the fourth quarter and fiscal 2011 are 23 cents and $1.61 per share.,0.017721330747008324,0.08529025316238403,0.8969884514808655,neutral,-0.06756892055273056
24,2012-01-24 05:30:00,Management now expects sales to increase approximately 8% in the fourth quarter and between 2% and 3% in fiscal 2011.,0.9402315020561218,0.015323503874242306,0.0444449782371521,positive,0.9249079823493958
25,2012-01-24 05:30:00,"Earlier, Lowe's had forecasted fiscal 2011 sales to increase by approximately 2%.",0.9466519951820374,0.016321059316396713,0.0370270274579525,positive,0.9303309321403503
26,2012-01-24 05:30:00,Lowe's expects comparable-store sales to remain flat or up 1% in the fourth quarter but to decline by 1% in fiscal 2011.,0.02021622657775879,0.9631357192993164,0.016647975891828537,negative,-0.9429194927215576
27,2012-01-24 05:30:00,Heavy job losses and reduced access to credit have lead to a sharp fall in consumer discretionary spending on big-ticket items.,0.017248114570975304,0.9693686366081238,0.013383188284933567,negative,-0.9521205425262451
28,2012-01-24 05:30:00,"With the global economic environment still struggling, we believe that spending on big remodeling projects will likely remain under pressure until the housing market stabilizes and consumer-spending rebounds.",0.09946662932634354,0.5092248320579529,0.39130857586860657,negative,-0.40975821018218994
29,2012-01-24 05:30:00,"Lowe's in the home improvement retailing business faces stiff competition from The Home Depot Inc. ( HD ), Sherwin-Williams Company and other home supply retailers on attributes such as location, price and quality of merchandise, in-stock consistency, merchandise assortments, and customer service.",0.23085999488830566,0.4673430621623993,0.30179694294929504,negative,-0.23648306727409363
30,2012-01-24 05:30:00,This may weigh upon the company's results.,0.028456132858991623,0.030578378587961197,0.9409655332565308,neutral,-0.002122245728969574
31,2012-01-24 05:30:00,Medical devices major St.Jude Medical ( STJ ) will stop enrolling new patients in its FAME II clinical trial following positive results from an interim analysis.,0.0204519834369421,0.7899847030639648,0.18956339359283447,negative,-0.7695327401161194
32,2012-01-24 05:30:00,"The independent data safety monitoring board (""DSMB"") recommended investigators to halt patient enrollment in the study following the impressive results which have shown statistically significant reduction in the need for hospital readmission and urgent revascularization when fractional flow reserve (""FFR"")-guided assessment is used in treating patients with coronary artery disease.",0.8055586218833923,0.06406848877668381,0.13037295639514923,positive,0.7414901256561279
33,2012-01-24 05:30:00,FFR is an index that identifies and measures the severity of coronary artery narrowing.,0.04093058779835701,0.006879557389765978,0.9521898627281189,neutral,0.03405103087425232
34,2012-01-24 05:30:00,It specifically locates the coronary narrowings which are responsible for occluding blood flow to a patient's heart muscle and directs the surgeons to identify the lesions requiring stenting.,0.03293155878782272,0.009128184989094734,0.9579402208328247,neutral,0.02380337379872799
35,2012-01-24 05:30:00,The approach is believed to help rein in healthcare costs and improve patient outcome.,0.9102427363395691,0.014870880171656609,0.07488630712032318,positive,0.8953718543052673
36,2012-01-24 05:30:00,The company-sponsored FAME II trial is evaluating the use of St. Jude's PressureWire FFR devices during the treatment of patient with stable coronary artery disease.,0.10365024209022522,0.009858998470008373,0.8864908218383789,neutral,0.09379124641418457
37,2012-01-24 05:30:00,"The objective of the trial is to study the role of FFR in treating this condition by comparing FFR-guided percutaneous coronary intervention (""PCI"") plus optimal medical therapy (""OMT"") with OMT alone.",0.3034561276435852,0.008483980782330036,0.68805992603302,neutral,0.29497215151786804
38,2012-01-24 05:30:00,The DSMB considered it unethical to continue randomize patients to OMT alone as patients experienced a highly statistically significant increased risk of hospital readmission and urgent revascularization.,0.037225574254989624,0.8779712319374084,0.08480320870876312,negative,-0.8407456874847412
39,2012-01-24 05:30:00,"The DSMB advised St. Jude to stop enrolling patients in the FAME II study given the higher risk of major adverse cardiac events in patients randomized to OMT alone versus ""FFR-guided PCI plus OMT"".",0.10941774398088455,0.4717370271682739,0.4188452363014221,negative,-0.36231929063796997
40,2012-01-24 05:30:00,The board concluded that this difference was highly unlikely to change with the enrollment of additional patients.,0.2380058914422989,0.05754808709025383,0.704446017742157,neutral,0.18045780062675476
41,2012-01-24 05:30:00,Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649 .,0.015015028417110443,0.011195102706551552,0.9737899303436279,neutral,0.0038199257105588913
42,2012-01-24 05:30:00,"About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.",0.5453232526779175,0.053687743842601776,0.4009890556335449,positive,0.4916355013847351
43,2012-01-24 05:30:00,"Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.",0.015234422869980335,0.010434982366859913,0.9743305444717407,neutral,0.004799440503120422
44,2012-01-24 05:30:00,Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.,0.06386703997850418,0.004654404241591692,0.9314785599708557,neutral,0.059212636202573776
45,2012-01-24 05:30:00,"Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks.",0.03399818018078804,0.004788470920175314,0.9612133502960205,neutral,0.02920970879495144
46,2012-01-24 05:30:00,Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance.,0.054108913987874985,0.005191051866859198,0.9407000541687012,neutral,0.04891786351799965
47,2012-01-24 05:30:00,Recommendations and target prices are six-month time horizons.,0.013092893175780773,0.007127966266125441,0.9797791242599487,neutral,0.0059649269096553326
48,2012-01-24 05:30:00,"Zacks ""Profit from the Pros"" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research.",0.027419384568929672,0.007709485478699207,0.9648711085319519,neutral,0.01970990002155304
49,2012-01-24 05:30:00,Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=7158 .,0.01714674010872841,0.013544849120080471,0.9693083763122559,neutral,0.0036018909886479378
50,2012-01-24 05:30:00,"Zacks.com is a property of Zacks Investment Research , Inc., which was formed in 1978 by Leonard Zacks.",0.01656932570040226,0.007216930855065584,0.976213812828064,neutral,0.009352395310997963
51,2012-01-24 05:30:00,As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results.,0.7956718802452087,0.01975652575492859,0.18457163870334625,positive,0.7759153842926025
52,2012-01-24 05:30:00,"Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank , which continues to outperform the market by nearly a 3 to 1 margin.",0.7777089476585388,0.016997475177049637,0.20529359579086304,positive,0.7607114911079407
53,2012-01-24 05:30:00,"The best way to unlock the profitable stock recommendations and market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros.",0.07881949096918106,0.006378026679158211,0.9148024916648865,neutral,0.072441466152668
54,2012-01-24 05:30:00,"In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time!",0.43368902802467346,0.012674679979681969,0.5536363124847412,neutral,0.42101433873176575
55,2012-01-24 05:30:00,Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4582 .,0.019364962354302406,0.015343000181019306,0.9652920365333557,neutral,0.0040219621732831
56,2012-01-24 05:30:00,Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.,0.01104306522756815,0.014137434773147106,0.9748194813728333,neutral,-0.0030943695455789566
57,2012-01-24 05:30:00,Disclaimer: Past performance does not guarantee future results.,0.027422117069363594,0.05681845545768738,0.9157593846321106,neutral,-0.029396338388323784
58,2012-01-24 05:30:00,Investors should always research companies and securities before making any investments.,0.044664014130830765,0.00805959664285183,0.9472764134407043,neutral,0.036604419350624084
59,2012-01-24 05:30:00,Nothing herein should be construed as an offer or solicitation to buy or sell any security.,0.018396001309156418,0.0089272977784276,0.972676694393158,neutral,0.009468703530728817
60,2012-01-24 05:30:00,To read this article on Zacks.com click here.,0.01796119473874569,0.0192450862377882,0.9627937078475952,neutral,-0.001283891499042511
61,2012-01-24 05:30:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
